What's Happening?
iQure Pharma, a biotech company focused on CNS disorders, has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research. The grant will support the investigation of EAAT2 modulation with iQ-007, a small molecule designed
to enhance EAAT2 activity, in Parkinson's disease models. The research aims to demonstrate the correlation between extracellular glutamate management and functional effects in Parkinson's disease. The project will be led by Henk de Wilde, with collaboration from Associate Professor Laura Civiero and Atuka Inc. The goal is to identify a clinical biomarker for patient treatment suitability.
Why It's Important?
This grant represents a significant step in advancing therapeutic approaches for Parkinson's disease, a condition affecting millions worldwide. By focusing on EAAT2 modulation, iQure Pharma aims to address glutamate imbalance, a key factor in neurodegenerative diseases. The research could lead to new treatment options for Parkinson's and other CNS disorders, potentially improving patient outcomes. The support from The Michael J. Fox Foundation underscores the importance of innovative research in finding effective treatments for Parkinson's disease.
What's Next?
iQure Pharma will conduct studies across multiple preclinical models to explore the effects of iQ-007 on Parkinson's disease pathways. The research will focus on identifying biomarkers that can predict patient response to treatment. Successful outcomes could lead to clinical trials and eventual commercialization of new therapies. The collaboration with experts in the field will enhance the research's credibility and impact, potentially attracting further funding and partnerships.
